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Reply from the authorLETTERS TO THE EDITOR
To the Editor: I appreciate the comments of Dr.
Nzerue regarding my “Nephrology Forum” discussion.
First, it should be emphasized that determining the anti-Calcium antagonists and
proteinuric effect is not the sole endpoint in defining renal
protection. The surrogate markers used to assess the effectrenal disease
of blood pressure reduction with calcium antagonists on
To the Editor: Epstein and his fellow discussants progression of diabetic renal disease include an increase
should be commended for a thorough review of calcium in glomerular membrane permeability as measured by al-
antagonists and renal failure [1]. However, I disagree buminuria and increases in mesangial matrix expansion as
with some of his views on the “ideal” renoprotection measured by renal biopsy. Surrogate markers serve as a
study. In reply to Dr. John Harrington’s question, Ep- guide to the direction in which renal function is headed
stein asserts that the ideal study of the renoprotective rather than a true endpoint of dialysis or death. Moreover,
effects of drugs like calcium channel blockers should changes in albuminuria depend on various factors, includ-
have a follow-up period of 4 to 5 years. While this sounds ing: (1) the agents used to lower blood pressure, (2) sodium
intake, and (3) the level to which blood pressure is reduced.theoretically sound, it is impractical. Clinically most pa-
Several studies have clearly demonstrated a dissociationtients with diabetes mellitus, especially type II diabetes,
between the rate of decline in renal excretory functionwho are prone to nephropathy would have reached end
and an antiproteinuric effect [1]. I believe that an empha-stage by the time such a study would have been con-
sis should be placed on measuring the ability of an inter-cluded [2]. We have shown that Dihydropyridine calcium
vention to delay the endpoints of time to dialysis or death.channel blockers (isradipine) worsened proteinuria
The author cites his study as indicative of the abilityamong proteinuric African American patients with type
of all calcium antagonists to worsen proteinuria [2]. In aII diabetes mellitus compared to an angiotensin con-
recent review, we have clearly demonstrated that in dia-verting enzyme inhibitor captopril [3].
betic patients with either microalbuminuria and/or macro-In our study, we showed that the differences in reno-
proteinuria, treatment with a dihydropyridine worsenedprotection between these drugs (anti-proteinuric action) proteinuria infrequently; rather, it more commonly ei-
were evident at three months and reached statistical sig- ther stabilized proteinuria or in a number of instances
nificance at six months. Thus, it is my view that within diminished proteinuria [3]. Furthermore, it should be
a year, credible differences between renoprotective med- pointed out that the formulation of isradipine utilized
icines should be evident for these projected effects to by Nzerue et al was not detailed. Based on the interval
be therapeutically useful for affected patients. of study, I assume it was probably an earlier formulation
Finally, the discussants neglected to mention that cal- of the drug that was not long-acting with a poor trough-
cium channel blockers can also cause acute renal failure peak (that is, not the currently available Dynacirc CR). It
by inducing interstitial nephritis [4,5]. is conceivable that these earlier formulations of calcium
antagonists that are not truly once-a-day with a lower
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trough-to-peak ratio may have different effects on renalMorehouse School of Medicine
function than the newer true once-a-day formulations.Atlanta, Georgia, USA
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